Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 1 Parkinson's papers of 244 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5158
Sealed predictions
- SMG1 in dopamine neurons, braak+0.21 (p 0.584) → +0.54 (p 0.136)receipt 5165
Swarm cases
receipt 5165: SMG1 in dopamine neurons, braak
- power
- full sample +0.31 (p 0.207, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.46 (p 0.054, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.51 (p 0.030, n 18). not the mix.
- skeptic
- leave-one-out range +0.21 to +0.41, sign flips 0; without severely affected donors +0.31 (p 0.207, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.60 (p 0.0089, n 18) vs +0.31 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SMG1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SMG1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.27 p 0.328 (needs p < 3.8e-4)
Receipts
loading the receipts